How does Ferinject®

make a difference?

Effective restoration of iron levels[1,9–32]

Proven data for efficacy and tolerability[1,9–32]

- Extensively studied in 26 interventional studies, published in peer-reviewed journals
- Market exposure estimated to > 2,200,000 patient years*

Rapid repletion of iron stores[9]

- More efficient repletion of iron stores with Ferinject® than with oral iron
- Faster increase in Hb with Ferinject® than with oral iron

Fast administration[1]

- Administration of 1000 mg iron in 15 minutes

Meaningful benefits that make a difference to patients' lives

Chronic Heart Failure

- Significant improvements in exercise capacity, symptoms and quality of life were sustained over a one-year period (FAIR-HF study: Ferinject® vs placebo; CONFIRM-HF study: Ferinject® vs placebo)[21,32]

IBD (inflammatory bowel disease)

- Significant improvement in overall quality of life from baseline (FERGIcor study: Ferinject® vs iron sucrose)[24]

Non-Dialysis Chronic Kidney Disease

- Significant reduction in the requirement for additional anaemia management, such as blood transfusion or ESA therapy over a one-year period (FIND-CKD study: Ferinject® vs oral iron)[20]

Women's Health

- Significant reduction in fatigue in non-anaemic women (PREFER study: Ferinject® vs placebo)[10]

ferinject®
ferric carboxymaltose

*Data on file: covers the period from international birth date to 31 December 2014

References: 1. Ferinject® Summary of Product Characteristics. 2. Quinibi WY. Arzneimittelforschung. 2010; 60(6a): 399–412. 3. Evstatiev R and Gasche C. Gut. 2012; 61(6): 933–52. 4. Patterson AJ et al. J Am Coll Nutr. 2001; 20(4): 337–42. 5. Brownlie T et al. Am J Clin Nutr. 2004; 79(3): 437–43. 6. Bruner AB et al. Lancet. 1996; 348(9033): 992–6. 7. Agarwal R. Am J Nephrol. 2007; 27(6): 565–71. 8. Verdon F et al. BMJ. 2003; 326(7399): 1124. 9. Quinibi WY et al. Nephrol Dial Transplant. 2011; 26(5): 1599–607. 10. Favrat B et al. PLoS One. 2014; 9(4): e94217. doi: 10.1371/journal.pone.0094217. eCollection 2014. 11. Breymann C et al. Int J Gynaecol Obstet. 2008; 101(1): 67–73. 12. Van Wyck DB et al. Obstet Gynecol. 2007; 110(2 Pt 1): 267–78. 13. Van Wyck DB et al. Transfusion. 2009; 49(12): 2719–28. 14. Seid MH et al. Am J Obstet Gynecol. 2008; 199(4): 435.e1–7. 15. Beshara S et al. Br J Haematol. 2003; 120(5): 853–9. 16. Covic A and Mircescu G. Nephrol Dial Transplant. 2010; 25(8): 2722–30. 17. Bailie GR et al. Hemodial Int. 2010; 14(1): 47–54. 18. Charytan C et al. Nephrol Dial Transplant. 2013; 28(4): 953–64. 19. Onken JE et al. Nephrol Dial Transplant. 2014; 29(4): 833–42. 20. Macdougall IC et al. Nephrol Dial Transplant. 2014. pii: gfu201. [Epub ahead of print]. 21. Anker SD et al. NEJM. 2009; 361(25): 2436–48. 22. Geisser P and Rumyantsev V. Arzneimittelforschung. 2010; 60(6a): 373–85. 23. Kulnigg S et al. Am J Gastroenterol. 2008; 103(5): 1182–92. 24. Evstatiev R et al. Gastroenterology. 2011; 141(3): 846–53.e1–2. 25. Evstatiev R et al. Clin Gastroenterol Hepatol. 2013; 11(3): 269–77. 26. Kulnigg-Dabsch S et al. Inflamm Bowel Dis. 2013; 19(8): 1609–16. 27. Allen RP et al. Sleep Med. 2011; 12(9): 906–13. 28. Geisser P et al. Arzneimittelforschung. 2010; 60(6a): 362–72. 29. Barish CF et al. Anemia. 2012; 2012: 172104. Epub 2012 Sep 10. 30. Hussain I et al. Anemia. 2013; 2013: 169107. Epub 2013 Aug 29. 31. Onken JR et al. Transfusion. 2014; 54(2): 306–15. 32. Ponikowski P et al. Eur Heart J. 2014 Aug 31. pii: ehu385. [Epub ahead of print].

Vifor Pharma

SINCE 1921

ferinject®
ferric carboxymaltose

ferinject®
ferric carboxymaltose

Their world awaits

How does Ferinject® help patients get back to what matters?

Ferinject® is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis must be based on laboratory tests.[1]

Vifor Pharma

SINCE 1921

Iron deficiency can change a

patient's world...

Iron deficiency / iron deficiency anaemia (ID / IDA) can be caused by blood loss, chronic inflammation, malabsorption and malnutrition[2]

Impact of ID / IDA on a patient's life:

Affects key organ function:[3]

- Potentially leading to lasting complications

Causes fatigue and exhaustion:[4,8]

- Significant physical, emotional and social consequences

Increases symptomatic burden:[4–7]

- Impaired physical performance
- Reduced cognitive function and failure to concentrate
- Cold intolerance

Impacts overall health and wellbeing:[4]

- Physiological effects go beyond fatigue

With Ferinject®

Their world awaits

- Reduction in fatigue[10]
- Improvement in exercise capacity[21,32]
- Improvement in quality of life[24]
- Reduction in requirement for further medical intervention[20]
- Established benefit-risk profile[20,32]
- Improved compliance vs standard treatment[23,24]

What are the tolerability considerations

with Ferinject®?

Ferinject® has an established benefit-risk profile

- 26 interventional studies, published in peer-reviewed journals[1,9–32]
- > 2,200,000 patient years' experience in post-marketing setting*
- Undesirable effects occur in <10% of Ferinject® subjects[1]
- Majority of undesirable effects have frequencies <1%[1]
- Anaphylactoid reactions occur in <0.1% of Ferinject® subjects[1]
- Recent studies with a one-year follow-up confirm the established benefit-risk profile[20,32]

How is Ferinject®

administered?

Effective recovery from ID / IDA, made convenient and manageable[1]

Ferinject® cumulative dosing based on Hb-value and body weight:[1]

Hb (g/dl)	Body weight 35 kg to <70 kg	Body weight ≥70 kg
<10	1500 mg iron	2000 mg iron
10<14	1000 mg iron	1500 mg iron
≥14	500 mg iron	500 mg iron

Ability to administer 1000 mg of iron in 15 minutes as a maximum daily dose[1]

- 1000 mg of Ferinject® can be given up to once a week

*Data on file: covers the period from international birth date to 31 December 2014

ferinject®
ferric carboxymaltose